Cargando…
Practical Considerations in the Administration of Aducanumab for the Neurologist
Aducanumab (Aduhelm), developed by the biotechnology firm Biogen in Cambridge, MA, was approved using the less common accelerated approval pathway by the Federal Drug Administration (FDA) reserved for treatments that fill a significant unmet need.(1) Its approval on June 7, 2021, has been met with a...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208401/ https://www.ncbi.nlm.nih.gov/pubmed/35733944 http://dx.doi.org/10.1212/CPJ.0000000000001144 |